Jerry S. Lanchbury - 25 Jun 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Chief Scientific Officer
Signature
By: Nathan A. Smith For: Jerry S. Lanchbury
Issuer symbol
MYGN
Transactions as of
25 Jun 2021
Net transactions value
-$1,690,716
Form type
4
Filing time
28 Jun 2021, 20:00:59 UTC
Next filing
30 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Options Exercise $415,879 +21,360 +8% $19.47 287,282 25 Jun 2021 Direct F1
transaction MYGN Common Stock Sale $693,559 -21,360 -7.4% $32.47 265,922 25 Jun 2021 Direct F1
transaction MYGN Common Stock Options Exercise $557,621 +28,640 +11% $19.47 294,562 25 Jun 2021 Direct F1
transaction MYGN Common Stock Sale $915,621 -28,640 -9.7% $31.97 265,922 25 Jun 2021 Direct F1
transaction MYGN Common Stock Sale $1,055,036 -33,372 -13% $31.61 232,550 25 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -21,360 -31% $0.000000 47,280 25 Jun 2021 Common Stock 21,360 $19.47 Direct F1, F3
transaction MYGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -28,640 -61% $0.000000 18,640 25 Jun 2021 Common Stock 28,640 $19.47 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.30 to $31.99, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The shares subject to this option are fully vested and exercisable.